Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1108-1115 , September 2009

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies

  • Katarina Le Blanc

      Affiliations

    • Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    • Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Corresponding Author InformationCorrespondence and reprint requests: Katarina Le Blanc, MD, PhD, Division of Clinical Immunology and Transfusion Medicine, F79, Karolinska University Hospital, Huddinge, SE-141 86 Stockholm, Sweden.
    • ,
  • A. John Barrett

      Affiliations

    • Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Marie Schaffer, PhD

      Affiliations

    • Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Hans Hägglund

      Affiliations

    • Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Division of Hematology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Per Ljungman

      Affiliations

    • Hematology Center, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Division of Hematology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Olle Ringdén

      Affiliations

    • Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    • Center for Allogeneic Stem Cell Research, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • Mats Remberger

      Affiliations

    • Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden

Received 19 February 2009 ,Accepted 15 May 2009.

References 

  1. Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood. 1998;91:3481–3486
  2. Kim DH, Kim JG, Sohn SK, et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol. 2004;125:217–224
  3. Kumar S, Chen MG, Gastineau DA, et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 2001;28:951–956
  4. Lee KH, Choi SJ, Lee JH, et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica. 2005;90:939–948
  5. Chakrabarti S, Brown J, Guttridge M, Pamphilon DH, Lankester A, Marks DI. Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback. Bone Marrow Transplant. 2003;32:23–30
  6. Savani BN, Mielke S, Rezvani K, et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:1216–1223
  7. Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007;21:2145–2152
  8. Jiang YZ, Barrett AJ, Goldman JM, Mavroudis DA. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol. 1997;74:1–6
  9. Sconocchia G, del Principe D, Barrett AJ. Non-classical antileukemia activity of early recovering NK cells after induction chemotherapy and HLA-identical stem cell transplantation in myeloid leukemias. Leukemia. 2006;20:1632–1633
  10. Niederwieser D, Gastl G, Rumpold H, Marth C, Kraft D, Huber C. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol. 1987;65:301–305
  11. Ruggeri L, Mancusi A, Burchielli E, Aversa F, Martelli MF, Velardi A. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol. 2007;19:142–147
  12. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992;39:225–235
  13. Schaffer M, Aldener-Cannava A, Remberger M, Ringden O, Olerup O. Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens. 2003;62:243–250
  14. Remberger M, Svahn BM, Mattsson J, Ringden O. Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation. 2004;78:122–127
  15. Remberger M, Svahn BM, Hentschke P, Lofgren C, Ringden O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24:823–830
  16. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;73:1729–1734
  17. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood. 1993;81:1094–1101
  18. Ringden O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant. 1995;15:619–625
  19. Remberger M, Ringden O, Blau IW, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood. 2001;98:1739–1745
  20. Hagglund H, Ringden O, Oman S, Remberger M, Carlens S, Mattsson J. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant. 1999;24:831–836
  21. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–828
  22. Ringden O. Management of graft-versus-host disease. Eur J Haematol. 1993;51:1–12
  23. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390–1397
  24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  25. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706
  26. Fine J, Gray R. Proportional hazard model for the sub-distribution of competing risks. J Am Stat Assoc. 1999;94:496–509
  27. Barrett AJ, Savani BN. Does chemotherapy modify the immune surveillance of hematological malignancies?. Leukemia. 2009;23:53–58
  28. Ringden O, Barrett AJ, Zhang MJ, et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol. 2003;121:874–885
  29. Remberger M, Ringden O, Ljungman P, et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;22:73–78
  30. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21:1733–1738
  31. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100
  32. Ringden O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22:416–423
  33. Ringden OT, Le Blanc K, Remberger M. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications. Exp Hematol. 2005;33:505–512

 Financial disclosure: See Acknowledgments on page 1114.

PII: S1083-8791(09)00254-7

doi: 10.1016/j.bbmt.2009.05.015

Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1108-1115 , September 2009

Article Tools

* Image Usage & Resolution